Cargando…
The clinical relevance of OSM in inflammatory diseases: a comprehensive review
Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570509/ https://www.ncbi.nlm.nih.gov/pubmed/37841259 http://dx.doi.org/10.3389/fimmu.2023.1239732 |
_version_ | 1785119784179859456 |
---|---|
author | Wolf, Cody L. Pruett, Clyde Lighter, Darren Jorcyk, Cheryl L. |
author_facet | Wolf, Cody L. Pruett, Clyde Lighter, Darren Jorcyk, Cheryl L. |
author_sort | Wolf, Cody L. |
collection | PubMed |
description | Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates a variety of signaling pathways including the JAK/STAT, MAPK, JNK, and PI3K/AKT pathways. Since its discovery in 1986, OSM has been identified as a significant contributor to a multitude of inflammatory diseases, including arthritis, inflammatory bowel disease, lung and skin disease, cardiovascular disease, and most recently, COVID-19. Additionally, OSM has also been extensively studied in the context of several cancer types including breast, cervical, ovarian, testicular, colon and gastrointestinal, brain,lung, skin, as well as other cancers. While OSM has been recognized as a significant contributor for each of these diseases, and studies have shown OSM inhibition is effective at treating or reducing symptoms, very few therapeutics have succeeded into clinical trials, and none have yet been approved by the FDA for treatment. In this review, we outline the role OSM plays in a variety of inflammatory diseases, including cancer, and outline the previous and current strategies for developing an inhibitor for OSM signaling. |
format | Online Article Text |
id | pubmed-10570509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105705092023-10-14 The clinical relevance of OSM in inflammatory diseases: a comprehensive review Wolf, Cody L. Pruett, Clyde Lighter, Darren Jorcyk, Cheryl L. Front Immunol Immunology Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates a variety of signaling pathways including the JAK/STAT, MAPK, JNK, and PI3K/AKT pathways. Since its discovery in 1986, OSM has been identified as a significant contributor to a multitude of inflammatory diseases, including arthritis, inflammatory bowel disease, lung and skin disease, cardiovascular disease, and most recently, COVID-19. Additionally, OSM has also been extensively studied in the context of several cancer types including breast, cervical, ovarian, testicular, colon and gastrointestinal, brain,lung, skin, as well as other cancers. While OSM has been recognized as a significant contributor for each of these diseases, and studies have shown OSM inhibition is effective at treating or reducing symptoms, very few therapeutics have succeeded into clinical trials, and none have yet been approved by the FDA for treatment. In this review, we outline the role OSM plays in a variety of inflammatory diseases, including cancer, and outline the previous and current strategies for developing an inhibitor for OSM signaling. Frontiers Media S.A. 2023-09-29 /pmc/articles/PMC10570509/ /pubmed/37841259 http://dx.doi.org/10.3389/fimmu.2023.1239732 Text en Copyright © 2023 Wolf, Pruett, Lighter and Jorcyk https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wolf, Cody L. Pruett, Clyde Lighter, Darren Jorcyk, Cheryl L. The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
title | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
title_full | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
title_fullStr | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
title_full_unstemmed | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
title_short | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
title_sort | clinical relevance of osm in inflammatory diseases: a comprehensive review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570509/ https://www.ncbi.nlm.nih.gov/pubmed/37841259 http://dx.doi.org/10.3389/fimmu.2023.1239732 |
work_keys_str_mv | AT wolfcodyl theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT pruettclyde theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT lighterdarren theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT jorcykcheryll theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT wolfcodyl clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT pruettclyde clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT lighterdarren clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT jorcykcheryll clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview |